Computational Filters in Lead Generation: Targeting Drug-Like Chemotypes

Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective

Volumn , Issue , 2005, Pages 325-339

  Guba, Wolfgang ^a   Roche, Olivier ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Chemogenomics; Computational filters in lead generation; Hard filters; Prioritization of chemotypes; Soft filters; Targeting drug like chemotypes

Indexed keywords

CHEMOGENOMICS; CHEMOTYPES; COMPUTATIONAL FILTER; LEAD GENERATION;

EID: 71049126586     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527603948.ch12     Document Type: Chapter

References (80)

1. S. Frantz, A. Smith, Nat. Rev. Drug Discov. 2003, 2, 95-96.
2. J. Drews, Drug Discov. Today 2003, 8, 411-420.
3. A. Alanine, M. Nettekoven, E. Roberts, A.W. Thomas, Comb.Chem. High Throughput Screen. 2003, 6, 51-66.
4. K.H. Bleicher, H.J. Böhm, K. Müller, A. Alanine, Nat. Rev. Drug Discov. 2003, 2, 369-378.
5. E. Jacoby, Quant. Struct.-Act. Relat. 2001, 20, 115-123.
6. E. Jacoby, A. Schuffenhauer, P. Floersheim, Drug News & Perspectives 2003, 16, 93-102.
7. T. Klabunde, G. Hessler, ChemBioChem 2002, 3, 928-944.
8. A. Schuffenhauer, J. Zimmermann, R. Stoop, J.-J. Van der Vyver, S. Lecchini, E. Jacoby, J. Chem. Inf.Comput. Sci. 2002, 42, 947-955.
9. A. Schuffenhauer, P. Floersheim, P. Acklin, E. Jacoby, J. Chem. Inf.Comput. Sci. 2003, 43, 391-405.
10. S.V. Frye, Chemistry & Biology 1999, 6, R3-R7.
11. G. Müller, Drug Discov. Today 2003, 8, 681-691.
12. D.E. Clark, P.D.J. Grootenhuis, Curr.Opin. Drug Discov. Dev. 2002, 5, 382-390.
13. D.E. Clark, S.D. Pickett, Drug Discov.Today 2000, 5, 49-58.
14. W.J. Egan, W.P. Walters, M.A. Murcko, Curr. Opin. Drug Discov.Dev. 2002, 5, 540-549.
15. A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski, J. Comb. Chem. 1999, 1, 55-68.
16. H. Matter, K.-H. Baringhaus, T. Naumann, T. Klabunde, B. Pirard, Comb. Chem. High Throughput Screen.2001, 4, 453-475.
17. T. Mitchell, G.A. Showell, Curr. Opin.Drug Discov. Dev. 2001, 4, 314-318.
18. W.P. Walters, A. Murcko, M.A. Murcko, Curr. Opin. Chem. Biol.1999, 3, 384-387.
19. W.P. Walters, M.A. Murcko, Adv. Drug Delivery Rev. 2002, 54, 255-271.
20. S. Ekins, C.L. Waller, P.W. Swaan, G. Cruciani, S.A. Wrighton, J.H. Wikel, J. Pharmacol. Toxicol.Methods 2000, 44, 251-272.
21. G.M. Rishton, Drug Discov. Today 1997, 2, 382-384.
22. G.M. Rishton, Drug Discov. Today 2002, 8, 86-96.
23. J. Seidler, S.L. McGovern, T.N. Doman, B.K. Shoichet, J. Med. Chem. 2003, 46, 4477-4486.
24. S.L. McGovern, B.T. Helfand, B. Feng, B.K. Shoichet, J. Med. Chem.2003, 46, 4265-4272.
25. S.L. McGovern, B.K. Shoichet, J. Med. Chem. 2003, 46, 1478-1483.
26. S.L. McGovern, E. Caselli, N. Grigorieff, B.K. Shoichet, J. Med. Chem. 2002, 45, 1712-1722.
27. O. Roche, P. Schneider, J. Zuegge, W. Guba, M. Kansy, A. Alanine, K. Bleicher, F. Danel, E.M. Gutknecht, M. Rogers-Evans, W. Neidhart, H. Stalder, M. Dillon, E. Sjogren, N. Fotouhi, P. Gillespie, R. Goodnow, W. Harris, P. Jones, M. Taniguchi, S. Tsujii, W. von der Saal, G. Zimmermann, G. Schneider, J. Med. Chem. 2002, 45, 137-142.
28. V.N. Viswanadhan, A.K. Ghose, G.R. Revankar, R.K. Robins, J. Chem.Inf. Comput. Sci. 1989, 29, 163-172.
29. A.K. Ghose, A. Pritchett, G.M. Crippen, J. Comput. Chem. 1988, 9, 80-90.
30. C.A. Lipinski, F. Lombardo, B.W. Dominy, P.J. Feeney, Adv. Drug Delivery Rev. 1997, 23, 3-25.
31. C.A. Lipinski, J. Pharmacol. Toxicol.Methods 2000, 44, 235-249.
32. M.C. Wenlock, R.P. Austin, P. Barton, A.M. Davis, P.D. Leeson, J. Med. Chem. 2003, 46, 1250-1256.
33. T.I. Oprea, J Comp.-Aided Mol. Des. 2002, 16, 325-334.
34. T.I. Oprea, A.M. Davis, S.J. Teague, P.D. Leeson, J. Chem. Inf. Comput. Sci.2001, 41, 1308-1315.
35. T.I. Oprea, J Comp.-Aided Mol. Des. 2000, 14, 251-264.
36. J.R. Proudfoot, Bioorg. Med. Chem. Lett.2002, 12, 1647-1650.
37. V.N. Viswanadhan, C. Balan, C. Hulme, J.C. Cheetham, Y. Sun, Curr.Opin. Drug Discov. Dev. 2002, 5, 400-406.
38. S.J. Teague, A.M. Davis, P.D. Leeson, T. Oprea, Angew. Chem., Int. Ed. 1999, 38, 3743-3748.
39. M.M. Hann, A.R. Leach, G. Harper, J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
40. Daylight Chemical Information Systems, Inc. 2002, http://www.daylight.com/.
41. Ajay, W.P. Walters, M.A. Murcko, J. Med. Chem. 1998, 41, 3314-3324.
42. J. Sadowski, H. Kubinyi, J. Med. Chem.1998, 41, 3325-3329.
43. H. van de Waterbeemd, E. Gifford, Nature Rev. Drug Discov. 2003, 2, 192-204.
44. R. Mannhold, H. Van de Waterbeemd, J. Comp.-Aided Mol. Des. 2001, 15, 337-354.
45. D.E. Clark, J. Pharm. Sci. 1999, 88, 807-814.
46. D.E. Clark, J. Pharm. Sci. 1999, 88, 815-821.
47. D.E. Clark, Drug Discov. Today 2003, 8, 927-933.
48. P. Ertl, B. Rohde, P. Selzer, Rational Approaches to Drug Design, Proceedings of the European Symposium on Quantitative Structure-Activity Relationships, 13th, Duesseldorf, Germany, Aug. 27- Sept. 1, 2000. 2001, 451-455.
49. N.A. Kratochwil, W. Huber, F. Muller, M. Kansy, P.R. Gerber, Biochem. Pharmacol. 2002, 64, 1355-1374.
50. http://www.moldiscovery.com/
51. P. Crivori, G. Cruciani, P.-A. Carrupt, B. Testa, J. Med. Chem. 2000, 43, 2204-2216.
52. G. Cruciani, M. Pastor, W. Guba, Eur. J. Pharmaceutical Sci. 2000, 11, S29-S39.
53. G. Cruciani, P. Crivori, P.A. Carrupt, B. Testa, THEOCHEM 2000, 503, 17-30.
54. G. Cruciani, M. Pastor, R. Mannhold, J. Med. Chem. 2002, 45, 2685-2694.
55. W. Guba, G. Cruciani, Molecular Modeling and Prediction of Bioactivity, Proceedings of the European Symposium on Quantitative Structure-Activity Relationships: Molecular Modeling and Prediction of Bioactivity, 12th, Copenhagen, Denmark, Aug. 23-28, 1998.2000, 89-94.
56. T.I. Oprea, J. Gottfries, Rational Approaches to Drug Design, Proceedings of the European Symposium on Quantitative Structure-Activity Relationships, 13th, Duesseldorf, Germany, Aug. 27- Sept. 1, 2000. 2001, 437-446.
57. T.I. Oprea, J. Gottfries, J. Comb. Chem.2001, 3, 157-166.
58. T.I. Oprea, I. Zamora, A.-L. Ungell, J. Comb. Chem. 2002, 4, 258-266.
59. T.I. Oprea, Curr. Opin. Chem. Biol. 2002, 6, 384-389.
60. http://www.fda.gov/cder/OPS/ BCS_guidance.htm.
61. B. Fermini, A.A. Fossa, Nature Rev.Drug Discov. 2003, 2, 439-447.
62. R. Webster, D. Leishman, D. Walker, Curr. Opin. Drug Discov. Dev. 2002, 5, 116-126.
63. I. Cavero, M. Mestre, J.-M. Guillon, W. Crumb, Exp. Opin. Pharmacother.2000, 1, 947-973.
64. G.M. Keseru, Bioorg. Med. Chem. Lett.2003, 13, 2773-2775.
65. O. Roche, G. Trube, J. Zuegge, P. Pflimlin, A. Alanine, G. Schneider, ChemBioChem 2002, 3, 455-459.
66. H. Yu, A. Adedoyin, Drug Discov. Today 2003, 8, 852-861.
67. M. Bertuccioli, S. Clementi, G. Cruciani, G. Giulietti, I. Rosi, Food Qual. Preference 1990, 2, 1-12.
68. V. Cecchetti, E. Filipponi, A. Fravolini, O. Tabarrini, D. Bonelli, M. Clementi, G. Cruciani, S. Clementi, J. Med. Chem. 1997, 40, 1698-1706.
69. L. Eriksson, E. Johansson, N. Kettaneh-Wold, S. Wold, Multi- and Megavariate Data Analysis: Principles and Applications, Umetrics AB, Umeå 2001.
70. DiverseSolutions version 4.0.9, http://www.tripos.com/
71. A.K. Ghose, G.M. Crippen, J. Comput. Chem. 1986, 7, 565-577.
72. A.K. Ghose, G.M. Crippen, J. Chem. Inf. Comput. Sci. 1987, 27, 21-35.
73. H. Kubinyi, Nature Rev. Drug Discov.2003, 2, 665-668.
74. R.A. Goodnow Jr., W. Guba, W. Haap, Comb. Chem. High Throughput Screen.2003, 6, 649-660.
75. U. Hoffrage, S. Lindsey, R. Hertwig, G. Gigerenzer, Science 2001, 292, 854-855.
76. S. Kurzenhauser, U. Hoffrage, Med. Teach. 2002, 24, 516-521.
77. U. Hoffrage, G. Gigerenzer, S. Krauss, L. Martignon, Cognition 2002, 84, 343-352.
78. U. Hoffrage, S. Lindsey, R. Hertwig, G. Gigerenzer, Science 2000, 290, 2261-2262.
79. G. Gigerenzer, U. Hoffrage, Psychol. Rev. 1999, 106, 425-430.
80. G. Gigerenzer, U. Hoffrage, Psychol.Rev. 1995, 102, 684-704.